Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Taeko Ueda is active.

Publication


Featured researches published by Taeko Ueda.


Current Opinion in Obstetrics & Gynecology | 2011

Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.

Hiroshi Tsujioka; Fusanori Yotsumoto; Shoko Hikita; Taeko Ueda; Masahide Kuroki; Shingo Miyamoto

Purpose of review Therapeutics targeting the ErbB protein family receptors have not always yielded favorable or successful results in present cancer therapy. This review discusses the possibility of the clinical adaptation of targeting against heparin-binding epidermal growth factor-like growth factor (HB-EGF), one of the ligands of the ErbB system, in ovarian cancer therapy. Recent findings We have previously described the results of studies concerning roles of HB-EGF in tumor formation in ovarian cancer. In brief, lisophosphatidic acid (LPA) and HB-EGF are predominantly expressed in advanced ovarian cancer, and LPA-induced, a disintegrin and metalloprotease-mediated ectodomain shedding of HB-EGF was found to be critical to tumor formation. We also noted that exogenous expression of HB-EGF enhanced tumor formation but inhibition blocked both extracellular signal-related kinase and serine/threonine protein kinase activation. Finally we investigated the antitumor effects of CRM197 – a specific HB-EGF inhibitor – on ovarian cancer cells by evaluating human ovarian cancer cell proliferation. Summary We discuss alternative strategies to develop the chemotherapeutic agent based on targeting ErbB family ligands rather than their receptors. A phase I study of CRM197 for advanced ovarian cancer has already begun, which is the first approved trial of ErbB-ligand-targeted therapy. We also discuss clinical adaptations based on combination of CRM197 with other conventional chemotherapeutic agents.


Taiwanese Journal of Obstetrics & Gynecology | 2012

Percutaneous cardiopulmonary support for pulmonary thromboembolism caused by large uterine leiomyomata

Masamitsu Kurakazu; Taeko Ueda; Kunihiro Matsuo; Hiroyasu Ishikura; Naoko Kumagai; Toshiyuki Yoshizato; Shingo Miyamoto

OBJECTIVE Acute pulmonary thromboembolism (PTE) is a common illness that causes death and disability. Deep vein thrombosis (DVT) is often found in patients with a large myomatous uterus, and can occasionally result in acute PTE. Here, we describe the achievement of a favorable outcome in a case of acute PTE. CASE REPORT The patient presented with acute PTE caused by a large uterine leiomyoma, without DVT of the lower extremities. Percutaneous cardiopulmonary support (PCPS) was used as an adjunct to thrombolytic therapy to treat the right ventricular thrombus with acute PTE. According to emergency practice, PCPS was initiated, and the patient was successfully treated with thrombolytic and anticoagulant therapy associated with total abdominal hysterectomy. CONCLUSIONS This case suggests that PCPS can lead to favorable clinical outcomes in patients with large uterine leiomyomata and severe PTE.


International Journal of Gynecological Cancer | 2009

Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer.

Hiroshi Tsujioka; Toru Hachisuga; Miyoko Fukuoka; Taeko Ueda; Daisuke Miyahara; Shinji Horiuchi; Kyoko Shirota; Toshiyuki Yoshizato; Makoto Emoto; Shingo Miyamoto; Tatsuhiko Kawarabayashi

Introduction: A high incidence of endometrial K-ras mutations has been reported in tamoxifen (TAM)-treated patients with breast cancer. We examined the changes in the frequency of the endometrial K-ras mutations after the cessation of TAM treatment. Methods: DNA was extracted from fresh cytological or polypectomy samples of the endometrium in 28 patients who had undergone TAM treatment of breast cancer. Mutations were detected by an enriched polymerase chain reaction-enzyme-linked minisequence assay (Sumitomo Metal Industry, Inc, Tokyo, Japan). K-ras codon 12 mutations were monitored in these 28 patients. Results: An initial examination detected endometrial K-ras mutations in 13 of the 28 patients. However, repeated examinations performed after cessation of TAM treatment did not detect endometrial K-ras mutations in any of these 13 patients. No endometrial K-ras mutation has been detected in the repeated examinations performed for these patients for more than 2 years since the cessation of TAM treatment. In addition, the 15 patients who did not have endometrial K-ras mutations in the initial examination did not demonstrate them in repeat examinations. Conclusions: The cessation of TAM treatment may reduce the risk of developing endometrial cancers through K-ras mutations.


International Journal of Women's Health | 2017

Effect of menopause on hormonal receptors in ampullae of the fallopian tube with a special reference to the p53 signature

Rie Urabe; Toru Hachisuga; Taeko Ueda; Toshinori Kawagoe; Tomoko Kurita; Seiji Kagami; Masanori Hisaoka; Yoshihisa Fujino

Objectives Age-related changes in the expression of hormonal receptors have not been well examined in the fallopian tube (FT). We herein report the effect of menopause on the hormone receptors in ampullae of the FTs (AFTs), in comparison with cortical inclusion cysts (CICs) of the ovary. Methods A total of 84 AFTs and 16 fimbriae of FTs, which were obtained from 26 premenopausal and 58 postmenopausal women; and 27 postmenopausal CICs were immunohistochemically studied for the expression of p53, Ki-67, estrogen receptor-alpha (ER-α), and progesterone receptor A (PRA). Apoptotic cells were identified using a TUNEL assay. Results Postmenopausal AFTs showed a significantly lower labeling index (LI) for Ki-67 (P<0.001), apoptosis (P=0.03), and PRA (P<0.001) than premenopausal AFTs. No significant correlation with immunohistochemical markers was found in premenopausal AFTs, but the LI for PRA was positively correlated with that for Ki-67 (P=0.004) and inversely with that for p53 (P=0.023) in postmenopausal AFTs. The expression of immunohistochemical markers was closely correlated between ampullae and fimbriae of the FT. The p53 signature (p53S) was detected in five postmenopausal AFTs (mean age: 70.2 years) and was not detected in any CICs. The immunohistochemical profile of p53S was low expression of Ki-67, apoptosis, and PRA, and high expression of ER-α. The expression of PRA in CICs was significantly higher than that in AFTs (P=0.001). Conclusion The expression of PRA was significantly lower in postmenopausal AFTs than in premenopausal AFTs, whereas the expression of PRA was well preserved in postmenopausal CICs.


Gynecologic oncology reports | 2014

Ovarian mucinous epithelial neoplasm showing immunohistochemical pattern of lower gastrointestinal origin with stromal minor sex-cord elements: A case report.

Taeko Ueda; Hitomi Nakagawa; Toru Hachisuga

Highlights • We report a case of an ovarian mucinous cystadenoma that exhibited extensive sex-cord differentiation.• The ovarian tumor coincided with a uterine endometrial carcinoma.• The immunohistochemical pattern of mucinous epithelium of the ovarian tumor was suggestive of lower gastrointestinal origin.


Anticancer Research | 2012

Clinical Significance of Cell-free and Concentrated Ascites Re-infusion Therapy for Advanced and Recurrent Gynecological Cancer

Taeko Ueda; Miyako Maehara; Yoko Takahashi; Naomi Nakayama; Haruhiko Kondo; Kyoko Shirota; Toshiyuki Yoshizato; Shingo Miyamoto


Anticancer Research | 2011

A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.

Hiroshi Tsujioka; Tatsuya Fukami; Fusanori Yotsumoto; Taeko Ueda; Shoko Hikita; Yoko Takahashi; Haruhiko Kondo; Masahide Kuroki; Shingo Miyamoto


Anticancer Research | 2015

Clinical Efficacy of Aprepitant in Patients with Gynecological Cancer after Chemotherapy Using Paclitaxel and Carboplatin.

Miyako Maehara; Taeko Ueda; Daisuke Miyahara; Yoko Takahashi; Kohei Miyata; Sung Ouk Nam; Takahiro Katsuda; Haruhiko Kondo; Shingo Miyamoto


Anticancer Research | 2011

Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA.

Shoko Hikita; Fusanori Yotsumoto; Tatsuya Fumaki; Shinji Horiuchi; Ayako Sanui; Kohei Miyata; Sung Ouk Nam; Hiroshi Tsujioka; Taeko Ueda; Kyoko Shirota; Toshiyuki Yoshizato; Kazuhiro Maeda; Toyokazu Ishikawa; Yoshinobu Okuno; Masahide Kuroki; Eisuke Mekada; Shingo Miyamoto


Anticancer Research | 2015

The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial

Daisuke Miyahara; Taeko Ueda; Takahiro Katsuda; Miyako Maehara; Satoshi Fukagawa; Kohei Miyata; Sung Ouk Nam; Haruhiko Kondo; Shingo Miyamoto

Collaboration


Dive into the Taeko Ueda's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rie Urabe

University of Occupational and Environmental Health Japan

View shared research outputs
Top Co-Authors

Avatar

Seiji Kagami

University of Occupational and Environmental Health Japan

View shared research outputs
Top Co-Authors

Avatar

Tomoko Kurita

University of Occupational and Environmental Health Japan

View shared research outputs
Researchain Logo
Decentralizing Knowledge